Immunoconjugates as an Efficient Platform for Drug Delivery: A Resurgence of Natural Products in Targeted Antitumor Therapy
Rositsa Mihaylova, Denitsa Momekova, Viktoria Elincheva, Georgi Momekov · 2024
Read Immunoconjugates as an Efficient Platform for Drug Delivery: A Resurgence of Natural Products in Targeted Antitumor Therapy by Rositsa Mihaylova, Denitsa Momekova, Viktoria Elincheva, Georgi Momekov (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11677665.txt.
Description
Rositsa Mihaylova and three co-authors review antibody drug conjugates in this 2024 paper. These constructs link a targeting antibody to a highly toxic payload, often a natural product too poisonous to give alone. The review walks through each part, antibody, linker, and payload, and how each shapes stability, effect, and safety. Resistance routes get their own analysis. The payload survey covers the validated natural compound classes, their structures, origins, and how they kill cells.
Targeting rests on tumor markers that act as addresses. The review maps those markers across blood and solid cancers and weighs their clinical value. Design challenges, present and emerging, close the survey. The field's premise is old drugs reborn: poisons once shelved for toxicity now work because the antibody carries them to the tumor. The authors present immunoconjugates as a growing platform rather than a single drug class.
Catalog record
| CREATOR | Rositsa Mihaylova, Denitsa Momekova, Viktoria Elincheva, Georgi Momekov |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 74 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |